Seeking Alpha

Progenix slips on mixed Q2, misses on revenue

  • Progenix Pharmaceuticals (PGNX -1.2%) slips after reporting a mixed Q2, coming in-line on a per share basis but missing on revenue.
  • Royalty income was $1.2M compared to $1.6M in Q212, largely based on net sales of Relistor.
  • Relistor global net sales increased 2% Q/Q, but fell by 27% Y/Y.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)